Barry S. Rosenstein

Germline polygenic score for prostate cancer aggressiveness

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study

The paper develops a polygenic risk model for prostate cancer using VA data and validates it in external cohorts, showing its clinical utility in risk stratification.

Prostate cancer risk stratification improved across multiple ancestries with new polygenic hazard score

The paper improves prostate cancer risk stratification across multiple ancestries using a new polygenic hazard score with additional SNPs, showing higher hazard ratios and positive predictive value for clinically significant prostate cancer.

Additional SNPs improve the performance of a polygenic hazard score for prostate cancer

This study improves a polygenic hazard score for prostate cancer by adding 120 SNPs, enhancing hazard ratios but not positive predictive value of PSA testing.

Large-scale transcriptome-wide association study identifies new prostate cancer risk regions

This study integrates a large prostate cancer GWAS with gene expression data to identify 235 genes associated with risk, prioritizing causal genes through Bayesian credible sets.